Prescott Group Capital Management L.L.C. Buys New Stake in 908 Devices Inc. (NASDAQ:MASS)

Prescott Group Capital Management L.L.C. purchased a new position in shares of 908 Devices Inc. (NASDAQ:MASS) during the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 150,000 shares of the company’s stock, valued at approximately $330,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MASS. Charles Schwab Investment Management Inc. grew its holdings in 908 Devices by 14.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 220,477 shares of the company’s stock valued at $765,000 after purchasing an additional 28,015 shares during the period. Geode Capital Management LLC grew its position in 908 Devices by 1.2% in the third quarter. Geode Capital Management LLC now owns 567,788 shares of the company’s stock valued at $1,970,000 after acquiring an additional 6,634 shares in the last quarter. State Street Corp increased its stake in 908 Devices by 1.2% during the 3rd quarter. State Street Corp now owns 479,044 shares of the company’s stock worth $1,662,000 after buying an additional 5,704 shares during the period. Barclays PLC increased its position in shares of 908 Devices by 452.7% during the third quarter. Barclays PLC now owns 46,214 shares of the company’s stock worth $160,000 after acquiring an additional 37,853 shares during the last quarter. Finally, Concurrent Investment Advisors LLC purchased a new stake in 908 Devices during the 4th quarter worth approximately $52,000. 88.06% of the stock is owned by hedge funds and other institutional investors.

908 Devices Stock Performance

Shares of NASDAQ:MASS opened at $3.01 on Friday. 908 Devices Inc. has a one year low of $1.81 and a one year high of $7.56. The company has a market capitalization of $104.82 million, a PE ratio of -1.70 and a beta of 0.99. The stock has a fifty day moving average of $2.51 and a 200-day moving average of $2.94.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of 908 Devices in a research report on Wednesday, February 19th. Stephens reaffirmed an “overweight” rating and issued a $6.00 target price on shares of 908 Devices in a research report on Wednesday, January 15th. Stifel Nicolaus dropped their price target on shares of 908 Devices from $17.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Leerink Partners restated a “market perform” rating and set a $4.00 price objective (down from $12.00) on shares of 908 Devices in a research note on Wednesday, November 13th. Finally, Leerink Partnrs cut 908 Devices from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 13th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, 908 Devices currently has an average rating of “Moderate Buy” and an average price target of $5.33.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.